Our Litigator of the Week this week is John O’Quinn of Kirkland & Ellis. On Tuesday, O’Quinn secured a preliminary injunction for Eli Lilly barring the U.S. Department of Health & Human Services from implementing a new “administrative dispute resolution” procedure to decide disputes between pharmaceutical companies and so-called “covered entities” under the 340B Drug Pricing Program.

The 340B program has been the source of considerable controversy of late. The program forces drug makers to offer steep discounts to certain health care providers that serve low-income, at-risk patients, in order to participate in Medicare and Medicaid. Pharmaceutical companies, however, contend that for-profit pharmacies have acted as middlemen in the program and pocketed billions in discounts meant for low-income consumers.